2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD28
  5. CD28 Agonist

CD28 Agonist

CD28 Agonists (2):

Cat. No. Product Name Effect Purity
  • HY-P9975
    Theralizumab
    		Agonist 99.46%
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.
  • HY-P991176
    RG-6333
    		Agonist
    RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003).